Search

Author/Creator Garon, E B

1. 1144PResponses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors. (23rd October 2018)

Authors:
Garon, E B; Wong, D J; Schneider, J G; Aljumaily, R; Korn, W M; Patel, M R; Autio, K A; Papadopoulos, K P; Naing, A; Gabrail, N; Munster, P N; Goldman, J; Hung, A; Oft, M; Leveque, J; Spigel, D R
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 1464PKEYNOTE-189 study of pembrolizumab (pembro) plus pemetrexed (pem) and platinum vs placebo plus pem and platinum for untreated, metastatic, nonsquamous NSCLC: Does choice of platinum affect outcomes?. (23rd October 2018)

Authors:
Rodriguez Abreu, D; Garassino, M C; Esteban, E; Speranza, G; Felip, E; Domine, M; Hochmair, M J; Powell, S F; Cheng, S Y-S; Bischoff, H; Peled, N; Hui, R; Reck, M; Garon, E B; Boyer, M; Grossi, F; Jennens, R; Yang, J; Pietanza, M C; Gadgeel, S M
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 531TiPCANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC. (24th November 2019)

Authors:
Cho, B C; Chang, G-C; Kim, Y-C; Geater, S; Saeteng, S; Yang, C-T; Goto, Y; Lu, S; Ardizzoni, A; Barlesi, F; De Marchi, P; Paz-Ares, L; Spigel, D R; Thomas, M; Garon, E B; Leung, M; Baum, J; Zewen, Z; Mookerjee, B; Yang, J C-H
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. (14th May 2019)

Authors:
Hastings, K; Yu, H A; Wei, W; Sanchez-Vega, F; DeVeaux, M; Choi, J; Rizvi, H; Lisberg, A; Truini, A; Lydon, C A; Liu, Z; Henick, B S; Wurtz, A; Cai, G; Plodkowski, A J; Long, N M; Halpenny, D F; Killam, J; Oliva, I; Schultz, N
Journal:
Annals of oncology
Issue:
Volume 30:Number 8(2019)
Page Start:
1311
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LBA4Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. (17th December 2018)

Authors:
Herbst, R S; Garon, E B; Kim, D-W; Chul Cho, B; Pérez Gracia, J L; Han, J-Y; Dubos Arvis, C; Majem, M; Forster, M; Monnet, I; Novello, S; Szalai, Z; Gubens, M A; Su, W-C; Ceresoli, G L; Samkari, A; Jensen, E; Lubiniecki, G M; Baas, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC. (15th December 2019)

Authors:
Gadgeel, S; Rodriguez-Abreu, D; Felip, E; Esteban, E; Speranza, G; Reck, M; Hui, R; Boyer, M; Garon, E B; Horinouchi, H; Cristescu, R; Aurora-Garg, D; Lunceford, J; Kobie, J; Ayers, M; Piperdi, B; Pietanza, M C; Garassino, M C
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 11
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. LBA52Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC). (23rd October 2018)

Authors:
Wolf, J; Seto, T; Han, J-Y; Reguart, N; Garon, E B; Groen, H J M; Tan, D S; Hida, T; de Jonge, M J A; Orlov, S V; Smit, E F; Souquet, P-J; Vansteenkiste, J F; Giovannini, M; Le Mouhaer, S; Robeva, A; Waldron-Lynch, M; Heist, R S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. LBA63Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). (23rd October 2018)

Authors:
Herbst, R S; Garon, E B; Kim, D-W; Chul Cho, B; Pérez Gracia, J L; Han, J-Y; Dubos Arvis, C; Majem, M; Forster, M; Monnet, I; Novello, S; Szalai, Z; Gubens, M A; Su, W-C; Ceresoli, G L; Samkari, A; Jensen, E; Lubiniecki, G M; Baas, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial. (18th January 2019)

Authors:
Herbst, R S; Baas, P; Perez-Gracia, J L; Felip, E; Kim, D -W; Han, J -Y; Molina, J R; Kim, J -H; Dubos Arvis, C; Ahn, M -J; Majem, M; Fidler, M J; Surmont, V; de Castro, G; Garrido, M; Shentu, Y; Emancipator, K; Samkari, A; Jensen, E H; Lubiniecki, G M
Journal:
Annals of oncology
Issue:
Volume 30:Number 2(2019)
Page Start:
281
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗